[A Case of Bullous Pemphigoid after Combined Chemotherapy of Durvalumab, Gemcitabine and Cisplatin for Intrahepatic Cholangiocarcinoma].

The patient is a 66-year-old man. He underwent a total of 9 courses of GCD therapy(gemcitabine+cisplatin+durvalumab)for intrahepatic cholangiocarcinoma with direct invasion of the greater omentum and abdominal wall and surrounding peritoneal dissemination. The tumor had shrunk and was judged to be curative, and laparoscopic hepatic S4a/S5 subsegmentectomy and S6 partial hepatectomy were performed at 8 months after the initial diagnosis. On the 24th postoperative day, pruritic petechial erythema appeared on the abdomen and lower extremities, some of which were accompanied by blisters. The patient tested positive for anti-BP180 antibody and was diagnosed as bullous pemphigoid. The skin rash improved after systemic steroid administration, and the patient is currently under observation. Bullous pemphigoid is a rare immune-related adverse event, but careful observation of skin symptoms is necessary for early detection.